Stock Price Quote

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE2340.0045.75 (+1.99 %)
PREV CLOSE ( ) 2294.25
OPEN PRICE ( ) 2335.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 9451
TODAY'S LOW / HIGH ( )2307.90 2341.00
52 WK LOW / HIGH ( )1794 2471.05
NSE2318.40-1.6 (-0.07 %)
PREV CLOSE( ) 2320.00
OPEN PRICE ( ) 2320.00
BID PRICE (QTY) 2318.40 (24)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 629081
TODAY'S LOW / HIGH( ) 2307.20 2341.60
52 WK LOW / HIGH ( )1792.6 2474
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-11 1977
Management Info
Glenn Saldanha - Chairman Glenn Saldanha - Managing Director
Registered Office

Address B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone 022 40189999

Email complianceofficer@glenmarkpharma.com

Website www.glenmarkpharma.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
 Listing : BSE, NSE

NEWS

10Aug Glenmark Pharmaceuticals informs about
Glenmark Pharmaceuticals has informed that the Company has allotted 23,8..
29Jul Glenmark Pharmaceuticals’ arm launches
Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceut..
29Jul Glenmark Pharmaceuticals rises as its
Glenmark Pharmaceuticals is currently trading at Rs. 2212.05, up by 27.1..
21Jul Glenmark Pharma’s arm gets USFDA’s nod
Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Specialty..
21Jul Glenmark Pharmaceuticals informs ab
Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A. (Gle..
MORE

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit7356.37-2007.99
Gross Profit 8661.02 -2660.71
Operating Profit 7286.6418494.21
Net Sales 24349.9384400.99
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Kwality Pharma (BSE)
peergroup  3444.75 (3.53%)
M.Cap ( in Cr)3574.34
Neuland Laboratories (BSE)
peergroup  23311.50 (0.38%)
M.Cap ( in Cr)29908.40
Ajanta Pharma (BSE)
peergroup  3675.15 (1.64%)
M.Cap ( in Cr)45924.32
Fredun Pharma (BSE)
peergroup  1547.75 (3.33%)
M.Cap ( in Cr)2559.68
Venus Remedies (BSE)
peergroup  1786.80 (2.86%)
M.Cap ( in Cr)2388.41
MORE

Shareholding Pattern

PROMOTERS 46.65%
MUTUAL FUNDS/UTI 16.76%
NON-INSTITUTION 13.81%
FI/BANKS/INSURANCE 1.12%
GOVERNMENT 0.04%
FII 0%
MORE

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. was incorporated in the year 1977. Its today's share price is 2340. Its current market capitalisation stands at Rs 66040.57 Cr. In the latest quarter, company has reported Gross Sales of Rs. 93132.45 Cr and Total Income of Rs.92121.22 Cr. The company's management includes Pradeep Kumar Sinha, Patricia Andrews, Dipankar Bhattacharjee, Vijayalakshmi Iyer, Saira Ramasastry, B E Saldanha, Cherylann Pinto, Anurag Mantri, Glenn Saldanha, Glenn Saldanha, Rashmi Khandelwal.

It is listed on the BSE with a BSE Code of 532296 , NSE with an NSE Symbol of GLENMARK and ISIN of INE935A01035. It's Registered office is at B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, Mumbai-400026, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Arthur Andersen & Associates, Price Waterhouse, Suresh Surana & Associates LLP, VK Bahri & Co, Walker Chandiok & Co LLP, Walker, Chandiok & Co, Walker, Chandiok & Co LLP

download beyond app
download beyond app
About Nirmal Bang About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support
Product & Services Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Algo Trading
Equity Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities
Derivatives Updates Market Report Overview
IPO IPO Issues Performance News & Analysis
Commodities Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges
Portfolio Management Service (PMS) NBSPL - PMS Disclosure Nirmal Bang PMS - Investor Charter NB PMS Insights SCORES complaints – July 2026 Online Grievance Portal – SCORES Online Dispute Resolution Portal – ODR Fee Calculator UPI ID - QR Code & Forms Empaneled Distributors Contact Us
Mutual Funds About Nirmal Bang Wealth Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy
NPS NPS Forms and Guidelines NPS-AML Policy NPS - Operational Guidelines
Nirmal Bang Research Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data Important Update IRRA
Other Links Disclaimer Privacy Policy Policies and Procedures Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SCORES and ‘SMARTODR portal
RMS Policy
RMS Policy Auto Square Off Policy
Inspection SORM Policy - NBEPL CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023 FY-2023-2024 FY-2024-2025 FY-2025-2026 FY-2026-2027
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker RA NBEPL Investor Charter RA NBSPL Investor Charter Investor Complaints -RA Investor Complaints-NBEPL Investor NBCPL Investor NBEPL RA Investor NBSPL-RA
Evoting
NSDL Evoting CDSL Evoting
Compliance Annual report
NBSPL ACR Report Signed Annexure – NBSPL NBEPL ACR Report Signed Annexure – NBEPL
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’s Surrendered List of AP’s KYC Activation Process Voluntary Freezing Blocking of Online Trading Account Internal Shortage Policy MCXCCL Client Reports Policy For GTC/GTD RBI Guidelines Transfer of Funds via SEBI-Validated UPI ID MTF Terms Master Circular for Online Dispute Resolution
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatment NBSPL Policy of AML NBEPL Policy of AML NBSPL Policy of Surveillance NBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For Any Legal Department Grievances – Level 1, Please Get In Touch With Mr. Bhavin Pandya On 022-6273 9232 Or Write A Mail To bhavin.pandya@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Legal Department Grievances – Level 2, Please Get In Touch With Mr. Kishor Kumar Agrawal On 022-6273 9252/9253 Or Write A Mail To kishorkumar.agrawal@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Compliance Grievances / other grievances , Please Get In Touch With Mr. Samir Kamdar On 022-62739395/9396 Or Write A Mail To samir.kamdar@nirmalbang.com With Subject line As Grievances/Complaint.     |    
IMPORTANT LINKS: SEBI BSE NSE MCX CDSL NSDL NCDEX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.